Cingulate, a company listed on the Nasdaq Capital Market under the symbol 'CING', has filed a prospectus supplement on March 18, 2024, to update its previous offering terms. The supplement amends the prior prospectus dated January 13, 2023, and the subsequent supplement dated May 5, 2023. The new filing allows Cingulate to offer and sell shares of common stock up to an aggregate offering price of $3,500,000 through H.C. Wainwright & Co., LLC, acting as the sales agent. This is in addition to the $4,969,120 worth of shares already sold under the previous prospectus. The public float of Cingulate's common stock was valued at $25,452,431.82 as of March 18, 2024, based on the closing price of $5.34 per share on January 18, 2024. However, the last reported sale price on March 15, 2024, was significantly lower at $1.13 per share.

Cingulate, a company listed on the Nasdaq Capital Market under the symbol 'CING', has filed a prospectus supplement on March 18, 2024, to update its previous offering terms. The supplement amends the prior prospectus dated January 13, 2023, and the subsequent supplement dated May 5, 2023. The new filing allows Cingulate to offer and sell shares of common stock up to an aggregate offering price of $3,500,000 through H.C. Wainwright & Co., LLC, acting as the sales agent. This is in addition to the $4,969,120 worth of shares already sold under the previous prospectus. The public float of Cingulate's common stock was valued at $25,452,431.82 as of March 18, 2024, based on the closing price of $5.34 per share on January 18, 2024. However, the last reported sale price on March 15, 2024, was significantly lower at $1.13 per share.